Business
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2
About this update from Pharvaris N.v.
[{"type":"text","content":"ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland. Details of the presentations are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning, M.D.Format: Poster Presentation, #22Date, time: Friday, July 11, 12:30-13:30 ETTitle: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension StudyPresenter: Michael E. Manning, M.D.Format: Poster Presentation, #20Date, time: Friday, July 11, 12:30-13:30 ETTitle: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema AttacksPresenter: H. Henry Li, M.D., Ph.D.Format: Poster Presentation, #5Date, time: Friday, July 11, 12:30-13:30 ETTitle: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension StudyPresenter: Marc A. Riedl, M.D., M.S.Format: Poster Presentation, #23Date, time: Friday, July 11, 12:30-13:30 ETTitle: Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacksPresenter: Joshua S. Jacobs, M.D.Format: Poster Presentation, #9Date, time: Friday, July 11, 12:30-13:30 ETTitle: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched AnalysisPresenter: Mark D. Scarupa, M.D. Format: Poster Presentation, #7Date, time: Friday, July 11, 12:30-13:30 ET The posters will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentat...